Tumor-Infiltrating Lymphocytes, CAR-, and T-Cell Receptor-Modified T Cells in Solid Cancer Oncology

2.

Kawakami

Y

,

Eliyahu

S

,

Delgado

CH

,

Robbins

PF

,

Rivoltini

L

,

Topalian

SL

, et al.

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

.

Proc Natl Acad Sci USA

.

1994

;

91

(

9

):

3515

–

9

.

3.

Kawakami

Y

,

Eliyahu

S

,

Sakaguchi

K

,

Robbins

PF

,

Rivoltini

L

,

Yannelli

JR

, et al.

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

.

J Exp Med

.

1994

;

180

(

1

):

347

–

52

.

4.

Drougkas

K

,

Karampinos

K

,

Karavolias

I

,

Koumprentziotis

IA

,

Ploumaki

I

,

Triantafyllou

E

, et al.

Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end

.

J Cancer Res Clin Oncol

.

2023

;

149

(

6

):

2709

–

34

.

5.

Maher

J

,

Davies

DM

.

CAR-based immunotherapy of solid tumours-A survey of the emerging targets

.

Cancers

.

2023

;

15

(

4

):

1171

.

6.

Klebanoff

CA

,

Chandran

SS

,

Baker

BM

,

Quezada

SA

,

Ribas

A

.

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

.

Nat Rev Drug Discov

.

2023

;

22

(

12

):

996

–

1017

.

7.

Rosenberg

SA

,

Packard

BS

,

Aebersold

PM

,

Solomon

D

,

Topalian

SL

,

Toy

ST

, et al.

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

.

N Engl J Med

.

1988

;

319

(

25

):

1676

–

80

.

8.

Wickstrom

S

,

Lovgren

T

.

Expansion of tumor-infiltrating lymphocytes from melanoma tumors

.

Methods Mol Biol

.

2019

;

1913

:

105

–

18

.

9.

Dudley

ME

,

Wunderlich

JR

,

Robbins

PF

,

Yang

JC

,

Hwu

P

,

Schwartzentruber

DJ

, et al.

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

.

Science

.

2002

;

298

(

5594

):

850

–

4

.

10.

Dafni

U

,

Michielin

O

,

Lluesma

SM

,

Tsourti

Z

,

Polydoropoulou

V

,

Karlis

D

, et al.

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

.

Ann Oncol

.

2019

;

30

(

12

):

1902

–

13

.

11.

Rosenberg

SA

,

Spiess

P

,

Lafreniere

R

.

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

.

Science

.

1986

;

233

(

4770

):

1318

–

21

.

12.

Rosenberg

SA

,

Yannelli

JR

,

Yang

JC

,

Topalian

SL

,

Schwartzentruber

DJ

,

Weber

JS

, et al.

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

.

J Natl Cancer Inst

.

1994

;

86

(

15

):

1159

–

66

.

13.

Chesney

J

,

Lewis

KD

,

Kluger

H

,

Hamid

O

,

Whitman

E

,

Thomas

S

, et al.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

.

J Immunother Cancer

.

2022

;

10

(

12

):

e005755

.

14.

Sarnaik

AA

,

Hamid

O

,

Khushalani

NI

,

Lewis

KD

,

Medina

T

,

Kluger

HM

, et al.

Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma

.

J Clin Oncol

.

2021

;

39

(

24

):

2656

–

66

.

15.

Aoki

Y

,

Takakuwa

K

,

Kodama

S

,

Tanaka

K

,

Takahashi

M

,

Tokunaga

A

, et al.

Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer

.

Cancer Res

.

1991

;

51

(

7

):

1934

–

9

.

16.

Jiang

SS

,

Tang

Y

,

Zhang

YJ

,

Weng

DS

,

Zhou

ZG

,

Pan

K

, et al.

A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma

.

Oncotarget

.

2015

;

6

(

38

):

41339

–

49

.

17.

Stevanovic

S

,

Draper

LM

,

Langhan

MM

,

Campbell

TE

,

Kwong

ML

,

Wunderlich

JR

, et al.

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells

.

J Clin Oncol

.

2015

;

33

(

14

):

1543

–

50

.

18.

Stevanovic

S

,

Helman

SR

,

Wunderlich

JR

,

Langhan

MM

,

Doran

SL

,

Kwong

MLM

, et al.

A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers

.

Clin Cancer Res

.

2019

;

25

(

5

):

1486

–

93

.

19.

Jazaeri

AA

,

Zsiros

E

,

Amaria

RN

,

Artz

AS

,

Edwards

RP

,

Wenham

RM

, et al.

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma

.

J Clin Oncol

.

2019

;

37

(

15_Suppl l

):

2538

.

20.

Creelan

BC

,

Wang

C

,

Teer

JK

,

Toloza

EM

,

Yao

J

,

Kim

S

, et al.

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

.

Nat Med

.

2021

;

27

(

8

):

1410

–

8

.

21.

Zacharakis

N

,

Huq

LM

,

Seitter

SJ

,

Kim

SP

,

Gartner

JJ

,

Sindiri

S

, et al.

Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes

.

J Clin Oncol

.

2022

;

40

(

16

):

1741

–

54

.

22.

Tran

KQ

,

Zhou

J

,

Durflinger

KH

,

Langhan

MM

,

Shelton

TE

,

Wunderlich

JR

, et al.

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

.

J Immunother

.

2008

;

31

(

8

):

742

–

51

.

23.

Shiravand

Y

,

Khodadadi

F

,

Kashani

SMA

,

Hosseini-Fard

SR

,

Hosseini

S

,

Sadeghirad

H

, et al.

Immune checkpoint inhibitors in cancer therapy

.

Curr Oncol

.

2022

;

29

(

5

):

3044

–

60

.

24.

Carlino

MS

,

Larkin

J

,

Long

GV

.

Immune checkpoint inhibitors in melanoma

.

Lancet

.

2021

;

398

(

10304

):

1002

–

14

.

25.

Ferris

RL

,

Blumenschein

G

Jr,

Fayette

J

,

Guigay

J

,

Colevas

AD

,

Licitra

L

, et al.

Nivolumab for recurrent squamous-cell carcinoma of the head and neck

.

N Engl J Med

.

2016

;

375

(

19

):

1856

–

67

.

26.

Rohaan

MW

,

Borch

TH

,

van den Berg

JH

,

Met

Ö

,

Kessels

R

,

Geukes Foppen

MH

, et al.

Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma

.

N Engl J Med

.

2022

;

387

(

23

):

2113

–

25

.

27.

Poschke

IC

,

Hassel

JC

,

Rodriguez-Ehrenfried

A

,

Lindner

KAM

,

Heras-Murillo

I

,

Appel

LM

, et al.

The outcome of ex vivo TIL expansion is highly influenced by spatial heterogeneity of the tumor T-cell repertoire and differences in intrinsic in vitro growth capacity between T-cell clones

.

Clin Cancer Res

.

2020

;

26

(

16

):

4289

–

301

.

28.

Tsuji

T

,

Eng

KH

,

Matsuzaki

J

,

Battaglia

S

,

Szender

JB

,

Miliotto

A

, et al.

Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer

.

Oncotarget

.

2020

;

11

(

27

):

2669

–

83

.

29.

Miller

BC

,

Sen

DR

,

Al Abosy

R

,

Bi

K

,

Virkud

YV

,

LaFleur

MW

, et al.

Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade

.

Nat Immunol

.

2019

;

20

(

3

):

326

–

36

.

30.

Daud

AI

,

Loo

K

,

Pauli

ML

,

Sanchez-Rodriguez

R

,

Sandoval

PM

,

Taravati

K

, et al.

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma

.

J Clin Investig

.

2016

;

126

(

9

):

3447

–

52

.

31.

Savas

P

,

Virassamy

B

,

Ye

C

,

Salim

A

,

Mintoff

CP

,

Caramia

F

, et al.

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

.

Nat Med

.

2018

;

24

(

7

):

986

–

93

.

32.

Sade-Feldman

M

,

Yizhak

K

,

Bjorgaard

SL

,

Ray

JP

,

de Boer

CG

,

Jenkins

RW

, et al.

Defining T cell states associated with response to checkpoint immunotherapy in melanoma

.

Cell

.

2018

;

175

(

4

):

998

–

1013 e20

.

33.

Krishna

S

,

Lowery

FJ

,

Copeland

AR

,

Bahadiroglu

E

,

Mukherjee

R

,

Jia

L

, et al.

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

.

Science

.

2020

;

370

(

6522

):

1328

–

34

.

34.

Barras

D

,

Ghisoni

E

,

Chiffelle

J

,

Orcurto

A

,

Dagher

J

,

Fahr

N

, et al.

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma

.

Sci Immunol

.

2024

;

9

(

92

):

eadg7995

.

35.

Martincorena

I

,

Campbell

PJ

.

Somatic mutation in cancer and normal cells

.

Science

.

2015

;

349

(

6255

):

1483

–

9

.

36.

Gokuldass

A

,

Draghi

A

,

Papp

K

,

Borch

TH

,

Nielsen

M

,

Westergaard

MCW

, et al.

Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander CD8(+) T cells in non-melanoma cancers compared to melanoma

.

Cancers

.

2020

;

12

(

11

):

3344

.

37.

Tran

E

,

Robbins

PF

,

Lu

YC

,

Prickett

TD

,

Gartner

JJ

,

Jia

L

, et al.

T-cell transfer therapy targeting mutant KRAS in cancer

.

N Engl J Med

.

2016

;

375

(

23

):

2255

–

62

.

38.

Tran

E

,

Turcotte

S

,

Gros

A

,

Robbins

PF

,

Lu

YC

,

Dudley

ME

, et al.

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

.

Science

.

2014

;

344

(

6184

):

641

–

5

.

39.

Zacharakis

N

,

Chinnasamy

H

,

Black

M

,

Xu

H

,

Lu

YC

,

Zheng

Z

, et al.

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

.

Nat Med

.

2018

;

24

(

6

):

724

–

30

.

40.

Kristensen

NP

,

Heeke

C

,

Tvingsholm

SA

,

Borch

A

,

Draghi

A

,

Crowther

MD

, et al.

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

.

J Clin Investig

.

2022

;

132

(

2

):

e150535

.

41.

Kim

SP

,

Vale

NR

,

Zacharakis

N

,

Krishna

S

,

Yu

Z

,

Gasmi

B

, et al.

Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors

.

Cancer Immunol Res

.

2022

;

10

(

8

):

932

–

46

.

42.

Lowery

FJ

,

Krishna

S

,

Yossef

R

,

Parikh

NB

,

Chatani

PD

,

Zacharakis

N

, et al.

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

.

Science

.

2022

;

375

(

6583

):

877

–

84

.

43.

Levin

N

,

Kim

SP

,

Marquardt

CA

,

Vale

NR

,

Yu

Z

,

Sindiri

S

, et al.

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes

.

J Immunother Cancer

.

2024

;

12

(

5

):

e008645

.

44.

Forget

MA

,

Tavera

RJ

,

Haymaker

C

,

Ramachandran

R

,

Malu

S

,

Zhang

M

, et al.

A novel method to generate and expand clinical-grade, genetically modified, tumor-infiltrating lymphocytes

.

Front Immunol

.

2017

;

8

:

908

.

45.

Tas

L

,

Jedema

I

,

Haanen

J

.

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers

.

Curr Opin Oncol

.

2023

;

35

(

2

):

107

–

13

.

46.

Beane

JD

,

Lee

G

,

Zheng

Z

,

Mendel

M

,

Abate-Daga

D

,

Bharathan

M

, et al.

Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma

.

Mol Ther

.

2015

;

23

(

8

):

1380

–

90

.

47.

Ritthipichai

K

,

Machin

M

,

Juillerat

A

,

Poirot

L

,

Fardis

M

,

Chartier

C

.

1052P Genetic Modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer

.

Ann Oncol

.

2020

;

31

:

S720

.

48.

Chamberlain

CA

,

Bennett

EP

,

Kverneland

AH

,

Svane

IM

,

Donia

M

,

Met

Ö

.

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

.

Mol Ther Oncolytics

.

2022

;

24

:

417

–

28

.

49.

Lin

S

,

Martinez

G

,

Forget

MA

,

Adlerz

K

,

Ghose

M

,

Williams

L

, et al.

Abstract 20: KSQ-001EX: an engineered TIL therapy manufactured from a clinical-scale, feeder-free process for the treatment of solid tumor indications

.

Cancer Res

.

2024

;

84

(

6_Suppl ment

):

20

.

50.

Burga

R

,

Khattar

M

,

Lajoie

S

,

Pedro

K

,

Foley

C

,

Ocando

AV

, et al.

166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo

.

J ImmunoTherapy Cancer

.

2021

;

9

:

A176

.

51.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

,

Jakubowiak

A

,

Agha

M

,

Cohen

AD

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet

.

2021

;

398

(

10297

):

314

–

24

.

52.

June

CH

,

Sadelain

M

.

Chimeric antigen receptor therapy

.

N Engl J Med

.

2018

;

379

(

1

):

64

–

73

.

53.

Majzner

RG

,

Mackall

CL

.

Clinical lessons learned from the first leg of the CAR T cell journey

.

Nat Med

.

2019

;

25

(

9

):

1341

–

55

.

54.

Munshi

NC

,

Anderson

LD

Jr,

Shah

N

,

Madduri

D

,

Berdeja

J

,

Lonial

S

, et al.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2021

;

384

(

8

):

705

–

16

.

55.

Marofi

F

,

Motavalli

R

,

Safonov

VA

,

Thangavelu

L

,

Yumashev

AV

,

Alexander

M

, et al.

CAR T cells in solid tumors: challenges and opportunities

.

Stem Cell Res Ther

.

2021

;

12

(

1

):

81

.

56.

Shah

PD

,

Huang

AC

,

Xu

X

,

Orlowski

R

,

Amaravadi

RK

,

Schuchter

LM

, et al.

Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma

.

Cancer Res Commun

.

2023

;

3

(

5

):

821

–

9

.

57.

Qi

C

,

Gong

J

,

Li

J

,

Liu

D

,

Qin

Y

,

Ge

S

, et al.

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

.

Nat Med

.

2022

;

28

(

6

):

1189

–

98

.

58.

Qi

C

,

Xie

T

,

Zhou

J

,

Wang

X

,

Gong

J

,

Zhang

X

, et al.

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer

.

J Hematol Oncol

.

2023

;

16

(

1

):

102

.

59.

Labanieh

L

,

Mackall

CL

.

CAR immune cells: design principles, resistance and the next generation

.

Nature

.

2023

;

614

(

7949

):

635

–

48

.

60.

Qi

C

,

Liu

C

,

Gong

J

,

Liu

D

,

Wang

X

,

Zhang

P

, et al.

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

.

Nat Med

.

2024

;

30

(

8

):

2224

–

34

.

61.

Del Bufalo

F

,

De Angelis

B

,

Caruana

I

,

Del Baldo

G

,

De Ioris

MA

,

Serra

A

, et al.

GD2-CART01 for relapsed or refractory high-risk neuroblastoma

.

N Engl J Med

.

2023

;

388

(

14

):

1284

–

95

.

62.

Zhao

Y

,

Shen

M

,

Wu

L

,

Yang

H

,

Yao

Y

,

Yang

Q

, et al.

Stromal cells in the tumor microenvironment: accomplices of tumor progression

.

Cell Death Dis

.

2023

;

14

(

9

):

587

.

63.

Bughda

R

,

Dimou

P

,

D’Souza

RR

,

Klampatsa

A

.

Fibroblast activation protein (FAP)-Targeted CAR-T cells: launching an attack on tumor stroma

.

Immunotargets Ther

.

2021

;

10

:

313

–

23

.

64.

Petrausch

U

,

Schuberth

PC

,

Hagedorn

C

,

Soltermann

A

,

Tomaszek

S

,

Stahel

R

, et al.

Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

.

BMC Cancer

.

2012

;

12

:

615

.

65.

Pircher

M

,

Schuberth

P

,

Gulati

P

,

Sulser

S

,

Weder

W

,

Curioni

A

, et al.

FAP-specific re-directed T cells first in-man study in malignant pleural mesothelioma: experience of the first patient treated

.

J Immunother Cancer

.

2015

;

3

(

S2

):

P120

.

66.

Narayan

V

,

Barber-Rotenberg

JS

,

Jung

IY

,

Lacey

SF

,

Rech

AJ

,

Davis

MM

, et al.

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

.

Nat Med

.

2022

;

28

(

4

):

724

–

34

.

67.

Pardoll

DM

.

The blockade of immune checkpoints in cancer immunotherapy

.

Nat Rev Cancer

.

2012

;

12

(

4

):

252

–

64

.

68.

Delgoffe

GM

,

Xu

C

,

Mackall

CL

,

Green

MR

,

Gottschalk

S

,

Speiser

DE

, et al.

The role of exhaustion in CAR T cell therapy

.

Cancer Cell

.

2021

;

39

(

7

):

885

–

8

.

69.

Majzner

RG

,

Mackall

CL

.

Tumor antigen escape from CAR T-cell therapy

.

Cancer Discov

.

2018

;

8

(

10

):

1219

–

26

.

70.

Bielamowicz

K

,

Fousek

K

,

Byrd

TT

,

Samaha

H

,

Mukherjee

M

,

Aware

N

, et al.

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

.

Neuro Oncol

.

2018

;

20

(

4

):

506

–

18

.

71.

Pang

N

,

Shi

J

,

Qin

L

,

Chen

A

,

Tang

Y

,

Yang

H

, et al.

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

.

J Hematol Oncol

.

2021

;

14

(

1

):

118

.

72.

Uslu

U

,

Castelli

S

,

June

CH

.

CAR T cell combination therapies to treat cancer

.

Cancer Cell

.

2024

;

42

(

8

):

1319

–

25

.

73.

Adusumilli

PS

,

Zauderer

MG

,

Rivière

I

,

Solomon

SB

,

Rusch

VW

,

O’Cearbhaill

RE

, et al.

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

.

Cancer Discov

.

2021

;

11

(

11

):

2748

–

63

.

74.

Curioni

A

,

Britschgi

C

,

Hiltbrunner

S

,

Bankel

L

,

Gulati

P

,

Weder

W

, et al.

A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells

.

Ann Oncol

.

2019

;

30

:

v501

.

75.

Gargett

T

,

Truong

NTH

,

Gardam

B

,

Yu

W

,

Ebert

LM

,

Johnson

A

, et al.

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

.

J Immunother Cancer

.

2024

;

12

(

5

):

e008659

.

76.

Haanen

JBAG

,

Mackensen

A

,

Schultze-Florey

C

,

Alsdorf

W

,

Wagner-Drouet

E

,

Heudobler

D

, et al.

611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors

.

Ann Oncol

.

2024

;

35

:

S489

–

90

.

77.

Mackensen

A

,

Haanen

JBAG

,

Koenecke

C

,

Alsdorf

W

,

Wagner-Drouet

E

,

Borchmann

P

, et al.

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

.

Nat Med

.

2023

;

29

(

11

):

2844

–

53

.

78.

Flugel

CL

,

Majzner

RG

,

Krenciute

G

,

Dotti

G

,

Riddell

SR

,

Wagner

DL

, et al.

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

.

Nat Rev Clin Oncol

.

2023

;

20

(

1

):

49

–

62

.

79.

Morgan

RA

,

Yang

JC

,

Kitano

M

,

Dudley

ME

,

Laurencot

CM

,

Rosenberg

SA

.

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

.

Mol Ther

.

2010

;

18

(

4

):

843

–

51

.

80.

Ahmed

N

,

Brawley

VS

,

Hegde

M

,

Robertson

C

,

Ghazi

A

,

Gerken

C

, et al.

Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma

.

J Clin Oncol

.

2015

;

33

(

15

):

1688

–

96

.

81.

Hegde

M

,

DeRenzo

CC

,

Zhang

H

,

Mata

M

,

Gerken

C

,

Shree

A

, et al.

Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma

.

J Clin Oncol

.

2017

;

35

(

15_Suppl l

):

10508

.

82.

Ronsley

R

,

Bertrand

KC

,

Song

EZ

,

Timpanaro

A

,

Choe

M

,

Tlais

D

, et al.

CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials

.

Cancer Metastasis Rev

.

2024

;

43

(

4

):

1205

–

16

.

83.

Bagley

SJ

,

Logun

M

,

Fraietta

JA

,

Wang

X

,

Desai

AS

,

Bagley

LJ

, et al.

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

.

Nat Med

.

2024

;

30

(

5

):

1320

–

9

.

84.

Katz

SC

,

Hardaway

J

,

Prince

E

,

Guha

P

,

Cunetta

M

,

Moody

A

, et al.

HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases

.

Cancer Gene Ther

.

2020

;

27

(

5

):

341

–

55

.

85.

Cherkassky

L

,

Hou

Z

,

Amador-Molina

A

,

Adusumilli

PS

.

Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors

.

Cancer Cell

.

2022

;

40

(

6

):

569

–

74

.

86.

Beatty

GL

,

Haas

AR

,

Maus

MV

,

Torigian

DA

,

Soulen

MC

,

Plesa

G

, et al.

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies

.

Cancer Immunol Res

.

2014

;

2

(

2

):

112

–

20

.

87.

Beatty

GL

,

O’Hara

MH

,

Lacey

SF

,

Torigian

DA

,

Nazimuddin

F

,

Chen

F

, et al.

Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial

.

Gastroenterology

.

2018

;

155

(

1

):

29

–

32

.

88.

Tchou

J

,

Zhao

Y

,

Levine

BL

,

Zhang

PJ

,

Davis

MM

,

Melenhorst

JJ

, et al.

Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer

.

Cancer Immunol Res

.

2017

;

5

(

12

):

1152

–

61

.

89.

Steffin

D

,

Ghatwai

N

,

Montalbano

A

,

Rathi

P

,

Courtney

AN

,

Arnett

AB

, et al.

Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers

.

Res Sq

.

2024

:rs.3.rs-4103623.

90.

Adusumilli

PS

,

Zauderer

MG

,

Rusch

VW

,

O’Cearbhaill

R

,

Zhu

A

,

Ngai

D

, et al.

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent

.

J Clin Oncol

.

2019

;

37

(

15_Suppl l

):

2511

.

91.

Johnson

LA

,

Morgan

RA

,

Dudley

ME

,

Cassard

L

,

Yang

JC

,

Hughes

MS

, et al.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

.

Blood

.

2009

;

114

(

3

):

535

–

46

.

92.

Morgan

RA

,

Dudley

ME

,

Wunderlich

JR

,

Hughes

MS

,

Yang

JC

,

Sherry

RM

, et al.

Cancer regression in patients after transfer of genetically engineered lymphocytes

.

Science

.

2006

;

314

(

5796

):

126

–

9

.

93.

Robbins

PF

,

Kassim

SH

,

Tran

TLN

,

Crystal

JS

,

Morgan

RA

,

Feldman

SA

, et al.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

.

Clin Cancer Res

.

2015

;

21

(

5

):

1019

–

27

.

94.

Robbins

PF

,

Morgan

RA

,

Feldman

SA

,

Yang

JC

,

Sherry

RM

,

Dudley

ME

, et al.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

.

J Clin Oncol

.

2011

;

29

(

7

):

917

–

24

.

95.

Lu

YC

,

Parker

LL

,

Lu

T

,

Zheng

Z

,

Toomey

MA

,

White

DE

, et al.

Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3

.

J Clin Oncol

.

2017

;

35

(

29

):

3322

–

9

.

96.

Morgan

RA

,

Chinnasamy

N

,

Abate-Daga

D

,

Gros

A

,

Robbins

PF

,

Zheng

Z

, et al.

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

.

J Immunother

.

2013

;

36

(

2

):

133

–

51

.

97.

Parkhurst

MR

,

Yang

JC

,

Langan

RC

,

Dudley

ME

,

Nathan

DAN

,

Feldman

SA

, et al.

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis

.

Mol Ther

.

2011

;

19

(

3

):

620

–

6

.

98.

Linette

GP

,

Stadtmauer

EA

,

Maus

MV

,

Rapoport

AP

,

Levine

BL

,

Emery

L

, et al.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

.

Blood

.

2013

;

122

(

6

):

863

–

71

.

99.

Provasi

E

,

Genovese

P

,

Lombardo

A

,

Magnani

Z

,

Liu

PQ

,

Reik

A

, et al.

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

.

Nat Med

.

2012

;

18

(

5

):

807

–

15

.

100.

Berdien

B

,

Mock

U

,

Atanackovic

D

,

Fehse

B

.

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

.

Gene Ther

.

2014

;

21

(

6

):

539

–

48

.

101.

Eyquem

J

,

Mansilla-Soto

J

,

Giavridis

T

,

van der Stegen

SJC

,

Hamieh

M

,

Cunanan

KM

, et al.

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

.

Nature

.

2017

;

543

(

7643

):

113

–

7

.

102.

Ruggiero

E

,

Carnevale

E

,

Prodeus

A

,

Magnani

ZI

,

Camisa

B

,

Merelli

I

, et al.

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function

.

Sci Transl Med

.

2022

;

14

(

631

):

eabg8027

.

103.

Schober

K

,

Müller

TR

,

Gökmen

F

,

Grassmann

S

,

Effenberger

M

,

Poltorak

M

, et al.

Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function

.

Nat Biomed Eng

.

2019

;

3

(

12

):

974

–

84

.

104.

Ishihara

M

,

Kitano

S

,

Kageyama

S

,

Miyahara

Y

,

Yamamoto

N

,

Kato

H

, et al.

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

.

J Immunother Cancer

.

2022

;

10

(

6

):

e003811

.

105.

Stadtmauer

EA

,

Fraietta

JA

,

Davis

MM

,

Cohen

AD

,

Weber

KL

,

Lancaster

E

, et al.

CRISPR-engineered T cells in patients with refractory cancer

.

Science

.

2020

;

367

(

6481

):

eaba7365

.

106.

Kieke

MC

,

Sundberg

E

,

Shusta

EV

,

Mariuzza

RA

,

Wittrup

KD

,

Kranz

DM

.

High affinity T cell receptors from yeast display libraries block T cell activation by superantigens

.

J Mol Biol

.

2001

;

307

(

5

):

1305

–

15

.

107.

Pan

Q

,

Weng

D

,

Liu

J

,

Han

Z

,

Ou

Y

,

Xu

B

, et al.

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A *02:01 patients with advanced soft tissue sarcoma

.

Cell Rep Med

.

2023

;

4

(

8

):

101133

.

108.

Blumenschein

GR

,

Devarakonda

S

,

Johnson

M

,

Moreno

V

,

Gainor

J

,

Edelman

MJ

, et al.

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer

.

J Immunother Cancer

.

2022

;

10

(

1

):

e003581

.

109.

Hong

DS

,

Butler

MO

,

Pachynski

RK

,

Sullivan

R

,

Kebriaei

P

,

Boross-Harmer

S

, et al.

Phase 1 clinical trial evaluating the safety and anti-tumor activity of ADP-A2M10 SPEAR T-cells in patients with MAGE-a10+ head and neck, melanoma, or urothelial tumors

.

Front Oncol

.

2022

;

12

:

818679

.

110.

Hong

DS

,

Van Tine

BA

,

Olszanski

AJ

,

Johnson

ML

,

Liebner

DA

,

Trivedi

T

, et al.

Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors

.

J Clin Oncol

.

2020

;

38

(

15_Suppl l

):

102

.

111.

Hong

DS

,

Van Tine

BA

,

Biswas

S

,

McAlpine

C

,

Johnson

ML

,

Olszanski

AJ

, et al.

Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial

.

Nat Med

.

2023

;

29

(

1

):

104

–

14

.

112.

D’Angelo

SP

,

Araujo

DM

,

Abdul Razak

AR

,

Agulnik

M

,

Attia

S

,

Blay

JY

, et al.

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

.

Lancet

.

2024

;

403

(

10435

):

1460

–

71

.

113.

Singh

N

.

Approval of the first TCR-based cell therapy

.

Mol Ther

.

2024

;

32

(

10

):

3195

.

114.

Baulu

E

,

Gardet

C

,

Chuvin

N

,

Depil

S

.

TCR-engineered T cell therapy in solid tumors: state of the art and perspectives

.

Sci Adv

.

2023

;

9

(

7

):

eadf3700

.

115.

Chandran

SS

,

Klebanoff

CA

.

T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance

.

Immunol Rev

.

2019

;

290

(

1

):

127

–

47

.

116.

Klebanoff

CA

,

Gattinoni

L

,

Restifo

NP

.

Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy

.

J Immunother

.

2012

;

35

(

9

):

651

–

60

.

117.

Kaluza

KM

,

Thompson

JM

,

Kottke

TJ

,

Flynn Gilmer

HC

,

Knutson

DL

,

Vile

RG

.

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants

.

Int J Cancer

.

2012

;

131

(

4

):

844

–

54

.

118.

Doran

SL

,

Stevanović

S

,

Adhikary

S

,

Gartner

JJ

,

Jia

L

,

Kwong

MLM

, et al.

T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study

.

J Clin Oncol

.

2019

;

37

(

30

):

2759

–

68

.

119.

Nagarsheth

NB

,

Norberg

SM

,

Sinkoe

AL

,

Adhikary

S

,

Meyer

TJ

,

Lack

JB

, et al.

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

.

Nat Med

.

2021

;

27

(

3

):

419

–

25

.

120.

Paulson

KG

,

Voillet

V

,

McAfee

MS

,

Hunter

DS

,

Wagener

FD

,

Perdicchio

M

, et al.

Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

.

Nat Commun

.

2018

;

9

(

1

):

3868

.

121.

Ma

Q

,

He

X

,

Zhang

B

,

Guo

F

,

Ou

X

,

Yang

Q

, et al.

A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis

.

Signal Transduct Target Ther

.

2022

;

7

(

1

):

380

.

122.

Hong

DS

,

Jalal

SI

,

Elimova

E

,

Ajani

JA

,

Blum Murphy

MA

,

Cervantes

A

, et al.

SURPASS-2 trial design: a phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers

.

J Clin Oncol

.

2022

;

40

(

4_Suppl l

):

TPS363

.

123.

Moore

K

,

Oaknin

A

,

Ray-Coquard

I

,

Coleman

RL

,

Herzog

TJ

,

O’malley

D

, et al.

#24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers

.

Int J Gynecol Cancer

.

2023

;

33

:

A407

–

8

.

124.

Hinrichs

CS

,

Borman

ZA

,

Cassard

L

,

Gattinoni

L

,

Spolski

R

,

Yu

Z

, et al.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity

.

Proc Natl Acad Sci USA

.

2009

;

106

(

41

):

17469

–

74

.

125.

Chen

Y

,

Yu

F

,

Jiang

Y

,

Chen

J

,

Wu

K

,

Chen

X

, et al.

Adoptive transfer of interleukin-21-stimulated human CD8+ T memory stem cells efficiently inhibits tumor growth

.

J Immunother

.

2018

;

41

(

6

):

274

–

83

.

126.

Hou

Y

,

Zak

J

,

Shi

Y

,

Pratumchai

I

,

Dinner

B

,

Wang

W

, et al.

Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy

.

bioRxiv

.

2023

:

2023.02.07.527459

.

127.

Legscha

KJ

,

Antunes Ferreira

E

,

Chamoun

A

,

Lang

A

,

Awwad

MHS

,

Ton

GNHQ

, et al.

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

.

J Immunother Cancer

.

2021

;

9

(

6

):

e001846

.

128.

Aggen

DH

,

Garcia

A

,

Saro Suarez

JM

,

Sauer

A

,

Cristiani

S

,

Elizabeth Brophy

F

, et al.

New phase 1 SURPASS trial cohort: early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma

. In:

2024 ASCO genitourinary cancers symposium

.

Journal of Clinical Oncology

;

2024

. p.

TPS708

.

129.

Nowicki

TS

,

Berent-Maoz

B

,

Cheung-Lau

G

,

Huang

RR

,

Wang

X

,

Tsoi

J

, et al.

A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab

.

Clin Cancer Res

.

2019

;

25

(

7

):

2096

–

108

.

130.

Foy

SP

,

Jacoby

K

,

Bota

DA

,

Hunter

T

,

Pan

Z

,

Stawiski

E

, et al.

Non-viral precision T cell receptor replacement for personalized cell therapy

.

Nature

.

2023

;

615

(

7953

):

687

–

96

.

131.

Leidner

R

,

Sanjuan Silva

N

,

Huang

H

,

Sprott

D

,

Zheng

C

,

Shih

YP

, et al.

Neoantigen T-cell receptor gene therapy in pancreatic cancer

.

N Engl J Med

.

2022

;

386

(

22

):

2112

–

9

.

132.

Meng

F

,

Zhao

J

,

Tan

AT

,

Hu

W

,

Wang

SY

,

Jin

J

, et al.

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial

.

Hepatol Int

.

2021

;

15

(

6

):

1402

–

12

.

133.

Veatch

J

,

Paulson

K

,

Asano

Y

,

Martin

L

,

Lee

B

,

Thomas Hall

E

, et al.

Merkel polyoma virus specific T-cell receptor transgenic T-cell therapy in PD-1 inhibitor refractory Merkel cell carcinoma

. In:

2022 ASCO annual meeting

.

Journal of Clinical Oncology

;

2022

. p.

9549

.